The Boston Scientific Spinal Cord Stimulator Litigation drew targeted filings from Carlson Law Firm PC and Wisner Baum LLP as plaintiffs' counsel build critical mass outside any MDL framework, alleging implantable neurostimulation devices cause severe tissue damage, lead migration, and neurological deterioration. The emergence of top-tier firms in this pre-consolidation phase signals strategic positioning for potential MDL formation, with claims centered on design and manufacturing defects in devices marketed for chronic pain management. This development runs parallel to the broader spinal cord stimulator litigation pending consolidation against both Boston Scientific and Abbott Laboratories, where plaintiffs allege similar device failures requiring surgical revision.
The Depo-Provera docket in MDL 3140 (N.D. Fla., Judge M. Casey Rodgers) absorbed 111 new complaints in a single day, with OnderLaw LLC filing 49 cases and Nigh Goldenberg Raso Vaughn PLLC adding 14 as the 3,099-case MDL accelerates toward resolution of Pfizer's pending preemption motion. Weitz & Luxenberg PC and Ben Martin Law Group contributed 13 and 11 filings respectively, while Morris James LLP, Dovel & Luner, and Douglas & London each registered four complaints. The FDA's December 2025 meningioma warning label update continues to undermine Pfizer's federal preemption defense as supplemental briefing ordered following September 2025 oral argument remains under advisement.
The EPA moved March 13 to weaken limits on ethylene oxide emissions, a regulatory rollback that directly undermines defense arguments that plaintiffs' alleged exposures fall below actionable thresholds. As plaintiffs pursue claims against sterilization facilities for lymphoma and leukemia, the new EPA position will complicate defense efforts to dispute causation at upcoming Daubert hearings. Plaintiffs are expected to seize on this retreat as evidence that industry pressure is overriding science, strengthening the litigation posture across the EtO sterilization docket.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
